Clinical trialPhase 2Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
- Outcome
- Stopped early. Results posted; no primary outcome with dataRecruitment challenges (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 15 March 2022
- Ended
- 27 August 2024
- Enrollment
- 22 participants
- Sites
- 80
- Primary outcomes
- Overall Response Rate (ORR) - Independent Central Review (ICR)
- Sponsor type
- Industry
- Results posted
- 29 October 2025
- Last update
- 29 October 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no primary outcome with dataAs posted on ClinicalTrials.gov ↗, registry record of 29 October 2025
- Primary outcome, no data
- Overall Response Rate (ORR) - Independent Central Review (ICR)The registry’s note: This endpoint was not assessed due to early study termination. Due to early study termination, data was not submitted for independent central review and therefore the overall response rate was done according to investigator assessment only and no independent central review was performed.
- Participants
- Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations: 22 started, 16 completed
- Serious adverse events
- Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations: 6 of 22Participants with at least one serious adverse event, of those at risk, as posted
10 secondary outcomes, the first 6 shown
- ORR · Overall Response Rate (ORR) - Investigator
- Complete Response (CR): Niraparib in Locally Advanced or Metast… 0/12 [Participants] (first of 4 rows)
- Duration of Response (DOR) - Investigator
- Niraparib in Locally Advanced or Metast… NA (NA to NA), n=2 [median Months, 95% Confidence Interval]
- PFS · Progression-Free Survival (PFS) - Investigator
- Niraparib in Locally Advanced or Metast… 3.3 (1.7 to NA), n=12 [median Months, 95% Confidence Interval]
- Clinical Benefit Rate (CBR) - Investigator and ICR
- Niraparib in Locally Advanced or Metast… 6/12 (21.1 to 78.9) [Participants]
- Number of Participants With Treatment-Emergent Adverse Events
- Niraparib in Locally Advanced or Metast… 22/22 [Participants]
- OS · Overall Survival (OS)
- Overall Survival at 6 Months: Niraparib in Locally Advanced or Metast… 81.8 (44.7 to 95.1), n=12 [Percentage, 95% Confidence Interval] (first of 2 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response Rate (ORR) - Independent Central Review (ICR) [Up to 4 years]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DOR) - Independent Central Review (ICR) [Up to 4 years]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival (PFS) - Independent Central Review (ICR) [Up to 4 years]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Response Rate (ORR) - Investigator [2 years 3 months]. Count Of Participants, Participants. Complete Response (CR): Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 0. Partial Response (PR): Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 2. Stable Disease (SD): Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 5. Progressive Disease (PD): Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 5.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DOR) - Investigator [2 years 3 months]. Median, Months (95% Confidence Interval). Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=2): NA (NA to NA) [Due to early study termination, there are a lack of participant events.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival (PFS) - Investigator [2 years 3 months]. Median, Months (95% Confidence Interval). Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 3.3 (1.7 to NA) [Due to early study termination, there are a lack of participant events.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Clinical Benefit Rate (CBR) - Investigator and ICR [2 years 3 months]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 6 (21.1 to 78.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
ORR With Untreated Measurable CNS Lesions - Investigator [Up to 4 years]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
ORR With Untreated Measurable CNS Lesions - ICR [Up to 4 years]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment-Emergent Adverse Events [2 years 3 months]. Count Of Participants, Participants. Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=22): 22.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) [6 months and 12 months]. Number, Percentage (95% Confidence Interval). Overall Survival at 6 Months: Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 81.8 (44.7 to 95.1). Overall Survival at 12 Months: Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (n=12): 51.9 (19.8 to 76.7).